Top Page
Suzhou Basecare Medical Corp. Ltd. Class H
(2170)
Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. S&P 500 (SPY)
Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model
Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 207.98M | 140.90M | 107.30M | 81.11M | 55.69M | Gross Profit |
| 91.35M | 59.53M | 51.15M | 27.71M | 26.25M | EBIT |
| -193.71M | -126.12M | -124.49M | -53.47M | -8.73M | EBITDA |
| -174.14M | -117.73M | -118.88M | -873.32M | -520.88M | Net Income Common Stockholders |
| -191.69M | -123.16M | -143.65M | -877.05M | -531.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 945.71M | 1.33B | 1.52B | 192.32M | 56.24M | Total Assets |
| 1.90B | 1.78B | 1.80B | 350.30M | 151.13M | Total Debt |
| 281.92M | 75.54M | 48.57M | 31.47M | 32.61M | Net Debt |
| -661.30M | -1.26B | -1.47B | -160.85M | 8.45M | Total Liabilities |
| 499.98M | 188.33M | 85.85M | 68.96M | 1.10B | Stockholders Equity |
| 1.40B | 1.59B | 1.72B | 281.33M | -938.85M |
| Cash Flow | Free Cash Flow | |||
| -371.44M | -317.52M | -234.71M | -72.38M | -40.51M | Operating Cash Flow |
| -267.23M | -188.77M | -197.85M | -64.29M | -38.15M | Investing Cash Flow |
| -324.81M | -88.70M | -56.60M | 33.53M | 16.77M | Financing Cash Flow |
| 190.55M | 23.51M | 1.60B | 207.47M | 26.49M |
Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis
Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$99.22B | 27.18 | 8.17% | ― | 7.52% | -1.92% | |
76 Outperform | $71.57B | 15.53 | 13.20% | 5.99% | -9.60% | -27.18% | |
74 Outperform | $30.26B | 10.46 | 14.56% | 5.66% | -5.37% | 6.28% | |
66 Neutral | $71.04B | 37.42 | 6.14% | 1.49% | 7.63% | -24.23% | |
61 Neutral | $8.71B | 8.24 | 14.96% | 6.03% | -10.67% | -19.27% | |
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
50 Neutral | HK$850.67M | ― | -18.64% | ― | 41.62% | -22.27% |
Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events
Suzhou Basecare Medical Corporation Limited has announced its 2024 Annual General Meeting (AGM) scheduled for June 5, 2025, where shareholders will consider and approve various resolutions, including financial reports, profit distribution plans, and the re-appointment of KPMG as the auditor. The AGM will also address the issuance of additional shares and amendments to the Articles of Association, reflecting the company’s strategic initiatives to enhance its operational and financial framework.
Suzhou Basecare Medical Corp. Ltd. has announced the 2025 first class meeting for holders of domestic shares and unlisted foreign shares, scheduled for June 5, 2025. The meeting aims to consider and approve proposed amendments to the Articles of Association, reflecting the company’s ongoing efforts to refine its governance structure. The outcome of this meeting could have significant implications for the company’s operational framework and its stakeholders.
Suzhou Basecare Medical Corporation Limited has announced the convening of its 2025 first class meeting for holders of H shares, scheduled for June 5, 2025. The meeting will address a special resolution to amend the Articles of Association, which could impact the company’s governance and operational structure. The results of the meeting will be published on the company’s and Hong Kong Exchanges’ websites, providing transparency to stakeholders.
Suzhou Basecare Medical Corporation Limited has received approval from the Jiangsu Medical Products Administration for its portable sperm quality analyzer, a device designed for home use to assess male fertility. This approval marks a significant step in the company’s expansion from professional medical institutions to general consumer applications, potentially broadening its market reach and enhancing its industry positioning.
Suzhou Basecare Medical Corp. Ltd. announced its audited consolidated results for the year ended December 31, 2024, showing a revenue increase to RMB 299,109,000 from RMB 207,976,000 in 2023, despite a loss for the year amounting to RMB 237,210,000. The company continues to expand its product pipeline through independent R&D and mergers and acquisitions, establishing itself as a key player in the global assisted reproduction industry by providing full-industry products at competitive prices, thereby contributing to human reproductive health.
Suzhou Basecare Medical Corp. Ltd. has announced an upcoming board meeting scheduled for March 28, 2025. The meeting will focus on reviewing and approving the company’s annual results for the year ending December 31, 2024, and discussing the potential recommendation of a final dividend. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market position and investor relations.
Suzhou Basecare Medical Corporation Limited has announced a strategic cooperation agreement with Rhea Labs Pte. Ltd. to expand its market in assisted reproductive technologies. The agreement aims to leverage both companies’ strengths to establish AI-powered IVF clinics in various regions, enhancing the company’s market position and benefiting shareholders.